文献速递乳腺癌

丹麦绝经后早期乳腺癌患者中芳香化酶抑制剂的缺血性心脏毒性:一项真实世界数据的队列研究

Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data.
PubMed 文献 · Lancet Oncol · 2024-01-01

该前瞻性队列研究纳入丹麦2009年1月1日至2020年12月31日诊断的绝经后早期乳腺癌患者,比较芳香化酶抑制剂治疗(AIT)与未接受AIT者的缺血性心脏毒性。在无心血管病史患者中,AIT组与未AIT组的两点主要不良心血管事件(MACE)调整HR为0.91(95%CI 0.73-1.14);有心血管病史患者中调整HR为0.81(95%CI 0.58-1.15)。作者认为结果不支持AIT具有临床相关缺血性心脏毒性,也不支持避免处方AIT。

要点

  • 无心血管病史患者中,AIT组MACE发生率4.3/1000人年,未AIT组4.1/1000人年,调整HR 0.91(95%CI 0.73-1.14)。
  • 有心血管病史患者中,AIT组MACE发生率12.4/1000人年,未AIT组12.1/1000人年,调整HR 0.81(95%CI 0.58-1.15)。
  • 作者认为结果不支持AIT具有临床相关缺血性心脏毒性,也不支持避免处方AIT。

核心结论

  • 作者认为研究结果不支持AIT在早期乳腺癌患者中具有临床相关的缺血性心脏毒性,也不支持避免对早期乳腺癌患者处方AIT。

研究设计与样本

  • 丹麦前瞻性队列研究,基于丹麦乳腺癌协作组(DBCG)临床数据库识别2009年1月1日至2020年12月31日诊断的绝经后乳腺癌患者并链接其他全国登记库。
  • 排除标准包括有其他原发癌史、在丹麦居住不足2年、未纳入DBCG治疗方案(包括转移性或局部晚期乳腺癌)。
  • 共识别43 440例绝经后乳腺癌患者,其中32 635例随访并纳入分析。
  • 按有无特定心血管疾病史(缺血性心脏病、缺血性卒中、心力衰竭)分层,主要结局为两点主要不良心血管事件(MACE;急性心肌梗死或缺血性卒中)。
  • 采用Cox比例风险回归模型以年龄为时间尺度,调整人口学特征、肿瘤特征及其他抗癌治疗,按意向性治疗分析估计病因特异性风险比(HR)。

主要发现

  • 无特定心血管疾病史的29 118例患者中,AIT组22 135例发生510例两点MACE(发生率4.3/1000人年),未AIT组6983例发生170例(4.1/1000人年),调整HR 0.91(95%CI 0.73-1.14)。
  • 有特定心血管疾病史的3517例患者中,AIT组2661例发生158例两点MACE(发生率12.4/1000人年),未AIT组856例发生50例(12.1/1000人年),调整HR 0.81(95%CI 0.58-1.15)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For aromatase inhibitor treatment (AIT) in breast cancer, there is an unresolved concern about ischaemic cardiotoxicity. We investigated the association between AIT and ischaemic cardiotoxicity in a prospective cohort of female patients with early breast cancer who received contemporary treatment in Denmark. METHODS: In this prospective cohort study in Denmark, we identified postmenopausal patients of any age diagnosed with breast cancer as recorded in the nationwide Danish Breast Cancer Cooperative Group (DBCG) clinical database between Jan 1, 2009, and Dec 31, 2020, and linked them to other nationwide registries. Exclusion criteria included having a history of other primary cancer, less than 2 years of residency in Denmark, and no inclusion in a treatment protocol according to the DBCG database, including for metastatic or locally advanced breast cancer. Information on demography, hospital diagnoses, filled prescriptions, laboratory testing, and socioeconomic status were recorded. We stratified the patient cohort according to history (yes vs no) of selected cardiovascular disease defined as ischaemic heart disease, ischaemic stroke, and heart failure, and defined the primary outcome as two-point major adverse cardiovascular events (MACE; acute myocardial infarction or ischaemic stroke). We estimated cause-specific hazard ratios (HRs) according to allocation to AIT versus not in an intention-to-treat analysis using a Cox proportional hazards regression model with age as the underlying time scale, adjusting for demographic characteristics, tumour characteristics, and other anti-cancer treatments. FINDINGS: 43 440 postmenopausal patients diagnosed with breast cancer were identified, of whom 32 635 were followed up and included in analyses. Of 29 118 postmenopausal patients with no history of selected cardiovascular disease, we observed 510 two-point MACEs among 22 135 patients allocated to AIT (incidence rate 4·3/1000 person-years of follow-up) and 170 two-point MACEs among 6983 patients not allocated to AIT (4·1/1000 person-years). The adjusted HR was 0·91 (95% CI 0·73-1·14) for patients allocated to AIT versus patients not allocated to AIT. Among 3517 patients with a history of selected cardiovascular disease, we observed 158 two-point MACEs among 2661 patients allocated to AIT (incidence rate 12·4/1000 person-years) and 50 two-point MACEs (12·1/1000 person-years) among 856 patients not allocated to AIT (adjusted HR 0·81 [95% CI 0·58-1·15]). INTERPRETATION: Our findings do not support a clinically relevant ischaemic cardiotoxic potential of AIT in patients with early breast cancer and do not support avoiding AIT prescription in patients with early breast cancer. FUNDING: Bispebjerg and Frederiksberg Hospital, Kræftens Bekæmpelse, Fonden til Lægevidenskabens Fremme, Aase og Ejnar Danielsens Fond, Helsefonden, and Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lund M, Corn G, Jensen MB, et al. Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data. Lancet Oncol. 2024. PMID: 39481396. doi:10.1016/S1470-2045(24)00491-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。